Healthcare
Live Price
Offline$0.0763
-4.16% today
Window Change
-70.78%
Window
Jun 26, 2025 → May 14, 2026
Coverage: 223 bars · Jun 26, 2025 → May 14, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Nuvation Bio Inc. (NUVB-WT) is a Healthcare stock with a market cap of $26.15M and listed on NYSE. The stock last traded around $0.08 and down 70.8% across the available one-year price window (Jun 26, 2025 → May 14, 2026). Baseline metrics include revenue growth of +699.0%, EPS growth of +71.6%, a dividend yield of 0.0%. What stands out right now is revenue +699.0%, EPS +71.6%, free cash flow -33.1% with operating margin -338.7% and ROIC -41.0%. Valuation already assumes a fairly strong business story at price/sales 24.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines NUVB-WT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NUVB-WT
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NUVB-WT Max Drawdown
-92.14%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for NUVB-WT and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$86.8M
+16.7% YoY
Free Cash Flow
-$68.5M
+29.0% YoY
Revenue Growth
+699.0%
EPS Growth
+71.6%
Gross Margin
86.6%
Net Margin
-325.3%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 63M | 8M | 0 | 0 | 0 |
| Gross Profit | 54M | 795K | 0 | 0 | 0 |
| Operating Income | -213M | -593M | -100M | -120M | -93M |
| EBITDA | -191M | -567M | -76M | -120M | -93M |
| Net Income | -205M | -568M | -76M | -104M | -87M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 164M | 36M | 43M | 101M | 132M |
| Total Assets | 595M | 541M | 621M | 672M | 776M |
| Total Liabilities | 289M | 77M | 16M | 17M | 30M |
| Shareholder Equity | 306M | 464M | 605M | 655M | 746M |
| Total Debt | 10M | 9M | 4M | 4M | 3M |
| Net Debt | -154M | -27M | -39M | -97M | -129M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
68M
+29.0% YoY
Capital Expenditures
282K
+23.8% YoY
Free Cash Flow
68M
+29.0% YoY
Key ratios
Gross Margin
86.6%
Operating Margin
-338.7%
Net Margin
-325.3%
ROE
-57.5%
Debt / Equity
0.03x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.